BUSINESS BITES: Zimmer becomes Zimmer Biomet; Amendia grows spine portfolio; Mindray MBO gathers pace
This article was originally published in Clinica
Zimmer has finally completed its merger with Biomet, creating Zimmer Biomet, the world's second largest orthopedics company after Johnson & Johnson's DePuy Synthes. The closing comes 14 months after Zimmer and Biomet's private equity owners inked the cash-and-equity deal. At that time, the deal was valued at around $13.35bn. Zimmer’s stock price has since risen over the past year and the final figure for the deal is closer to $14bn. The announcement follows the news that it was offloading the US business of its unicompartmental high flex knee (ZUK) line to Smith & Nephew, for an undisclosed sum. The transaction was part of Zimmer’s efforts to appease US anti-trust authorities. Additionally, DJO Global said it had entered into an agreement to purchase the Biomet Cobalt bone cement, Optivac Cement Mixing Accessories and Discovery elbow system for the US market. Discovery will be DJO’s first elbow technology. That deal will close within the next 10 days, DJO said.
You may also be interested in...
The latest updates to the US Open Payments database show spending by device and diagnostics firms on physician royalties, consulting fees, education, research and more was a bit less in 2016 compared to 2015, but still substantial. Top "general payment" spending came from Medtronic, Zimmer Biomet, Johnson & Johnson, Stryker, Smith & Nephew and Intuitive Surgical; while top "research payments" were reported by Edwards Lifesciences, Boston Scientific, and Abbott Laboratories, according to the CMS database.
Zimmer Biomet's response to a US FDA Form-483 says the firm was unaware of the quality systems woes at the targeted Biomet Warsaw, Ind., plant before its 2015 acquisition of the company. But, it emphasized, comprehensive fixes were in the works even before the 2016 agency inspection that generated more than a dozen substantive observations took place.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.